Research Analysts Set Expectations for VYGR FY2025 Earnings

Voyager Therapeutics, Inc. (NASDAQ:VYGR) – Investment analysts at HC Wainwright lowered their FY2025 earnings estimates for shares of Voyager Therapeutics in a research note issued on Wednesday, November 12th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings of ($1.98) per share for the year, down from their prior estimate of ($1.77). HC Wainwright currently has a “Buy” rating and a $25.00 target price on the stock. The consensus estimate for Voyager Therapeutics’ current full-year earnings is ($0.91) per share. HC Wainwright also issued estimates for Voyager Therapeutics’ Q4 2025 earnings at ($0.41) EPS, Q1 2026 earnings at ($0.30) EPS, Q2 2026 earnings at ($0.30) EPS, Q3 2026 earnings at ($0.30) EPS, Q4 2026 earnings at ($0.28) EPS, FY2026 earnings at ($1.18) EPS, FY2027 earnings at ($1.17) EPS, FY2028 earnings at ($1.49) EPS and FY2029 earnings at ($1.30) EPS.

Several other equities research analysts have also commented on the stock. Wall Street Zen raised shares of Voyager Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday. Weiss Ratings reiterated a “sell (d)” rating on shares of Voyager Therapeutics in a report on Wednesday, October 8th. Finally, Wedbush reissued an “outperform” rating and issued a $8.00 price target on shares of Voyager Therapeutics in a research report on Tuesday, November 11th. Six equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $12.12.

Voyager Therapeutics Stock Up 4.1%

Shares of VYGR opened at $4.28 on Monday. Voyager Therapeutics has a twelve month low of $2.64 and a twelve month high of $7.44. The stock has a market capitalization of $237.97 million, a P/E ratio of -1.98 and a beta of 0.95. The firm has a fifty day simple moving average of $4.55 and a two-hundred day simple moving average of $3.74.

Voyager Therapeutics (NASDAQ:VYGR) last posted its quarterly earnings results on Monday, November 10th. The company reported ($0.47) earnings per share for the quarter, topping the consensus estimate of ($0.53) by $0.06. Voyager Therapeutics had a negative net margin of 404.85% and a negative return on equity of 48.94%. The business had revenue of $11.15 million during the quarter, compared to the consensus estimate of $7.86 million.

Institutional Trading of Voyager Therapeutics

Several institutional investors have recently added to or reduced their stakes in VYGR. Wexford Capital LP purchased a new position in shares of Voyager Therapeutics in the third quarter worth $42,000. Jain Global LLC increased its holdings in Voyager Therapeutics by 44.1% in the 3rd quarter. Jain Global LLC now owns 28,104 shares of the company’s stock worth $131,000 after buying an additional 8,600 shares in the last quarter. Virtu Financial LLC bought a new stake in Voyager Therapeutics in the 3rd quarter worth about $93,000. Fiduciary Trust Co raised its position in Voyager Therapeutics by 28.9% in the 3rd quarter. Fiduciary Trust Co now owns 334,397 shares of the company’s stock worth $1,562,000 after buying an additional 75,000 shares during the last quarter. Finally, Two Sigma Investments LP bought a new position in Voyager Therapeutics during the 3rd quarter valued at about $657,000. 48.03% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Voyager Therapeutics

In related news, CFO Nathan D. Jorgensen sold 7,666 shares of the firm’s stock in a transaction that occurred on Friday, October 3rd. The shares were sold at an average price of $4.78, for a total transaction of $36,643.48. Following the completion of the sale, the chief financial officer owned 123,834 shares of the company’s stock, valued at $591,926.52. This trade represents a 5.83% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 4.53% of the stock is currently owned by insiders.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.